ACADIA Pharmaceuticals Inc. (ACAD)

17.47
NASDAQ : Health Technology
Prev Close 17.47
Day Low/High 0.00 / 0.00
52 Wk Low/High 14.51 / 41.20
Avg Volume 3.18M
Exchange NASDAQ
Shares Outstanding 124.83M
Market Cap 2.21B
EPS -2.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

June 8th Options Now Available For Acadia Pharmaceuticals (ACAD)

Investors in Acadia Pharmaceuticals Inc saw new options become available today, for the June 8th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACAD options chain for the new June 8th contracts and identified the following call contract of particular interest.

Lennar, LG Homes, GrubHub, Sprint: 'Mad Money' Lightning Round

Lennar, LG Homes, GrubHub, Sprint: 'Mad Money' Lightning Round

Jim Cramer looks at Lennar, LG Homes, GrubHub, Sprint, Acadia Pharmaceuticals, Pilgrim's Pride, Opko Health and more.

A Flash Flood of Selling: Cramer's 'Mad Money' Recap (Thursday 4/19/18)

A Flash Flood of Selling: Cramer's 'Mad Money' Recap (Thursday 4/19/18)

Interest rates, inflation and bonds all add up, says Jim Cramer. And now, the trade war with China's getting ugly.

ACADIA Pharmaceuticals To Present At The 17th Annual Needham Healthcare Conference On March 27, 2018

ACADIA Pharmaceuticals To Present At The 17th Annual Needham Healthcare Conference On March 27, 2018

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today...

Acadia Pharmaceuticals Stock Sees Short Interest Move 10.7% Lower

Acadia Pharmaceuticals Stock Sees Short Interest Move 10.7% Lower

The most recent short interest data has been released for the 02/28/2018 settlement date, which shows a 1,239,260 share decrease in total short interest for Acadia Pharmaceuticals Inc , to 10,355,126, a decrease of 10.69% since 02/15/2018. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

3 Good Bargain Stocks With Insider Buying

3 Good Bargain Stocks With Insider Buying

I continue to keep a 'shopping list' at the ready for the next dip in the market.

ACADIA Pharmaceuticals To Present At The Cowen And Company 38th Annual Health Care Conference On March 13, 2018

ACADIA Pharmaceuticals To Present At The Cowen And Company 38th Annual Health Care Conference On March 13, 2018

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today...

ACADIA Pharmaceuticals Reports Fourth Quarter And Full Year 2017 Financial Results

ACADIA Pharmaceuticals Reports Fourth Quarter And Full Year 2017 Financial Results

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders,...

ACADIA Pharmaceuticals To Announce Fourth Quarter And Full Year 2017 Financial Results On February 27, 2018

ACADIA Pharmaceuticals To Announce Fourth Quarter And Full Year 2017 Financial Results On February 27, 2018

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today...

These 2 Biotech Stocks Still Have Upside

These 2 Biotech Stocks Still Have Upside

The biotech sector has seen a big rally, but there are still opportunities.

ACADIA Pharmaceuticals To Present At The 36th Annual J.P. Morgan Healthcare Conference On January 9, 2018

ACADIA Pharmaceuticals To Present At The 36th Annual J.P. Morgan Healthcare Conference On January 9, 2018

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today...

January Setting Up to Be a Volatile Month

Sentiment readings are at extreme levels with the chance for overbought conditions heading into the New Year.

Damien McDevitt, Ph.D., Senior Vice President, Corporate Development (Photo: Business Wire)

Damien McDevitt, Ph.D., Senior Vice President, Corporate Development (Photo: Business Wire)

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders,...

What's Holding Up This Market?: Cramer's 'Mad Money' Recap (Monday 12/11/17)

What's Holding Up This Market?: Cramer's 'Mad Money' Recap (Monday 12/11/17)

It's just very hard to keep stocks down in this environment, says Jim Cramer. It's part of a synchronized global expansion.

ACADIA Pharmaceuticals To Present At The 29th Annual Piper Jaffray Healthcare Conference On November 28, 2017

ACADIA Pharmaceuticals To Present At The 29th Annual Piper Jaffray Healthcare Conference On November 28, 2017

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today...

Acadia, Dynavax Make the Biotech Mailbag

Acadia, Dynavax Make the Biotech Mailbag

Readers have asked about Acadia Pharmaceuticals and Dynavax Technologies, so we answer.

ACADIA Pharmaceuticals Reports Third Quarter 2017 Financial Results

ACADIA Pharmaceuticals Reports Third Quarter 2017 Financial Results

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders,...

ACADIA Pharmaceuticals Presents Data From The Phase II Study Of Pimavanserin In Alzheimer's Disease Psychosis At The Clinical Trials On Alzheimer's Disease (CTAD) 2017 Meeting

ACADIA Pharmaceuticals Presents Data From The Phase II Study Of Pimavanserin In Alzheimer's Disease Psychosis At The Clinical Trials On Alzheimer's Disease (CTAD) 2017 Meeting

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders,...

ACADIA Pharmaceuticals To Announce Third Quarter 2017 Financial Results On November 7, 2017

ACADIA Pharmaceuticals To Announce Third Quarter 2017 Financial Results On November 7, 2017

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today...

Short Interest Plummets 60.7% For ACAD

Short Interest Plummets 60.7% For ACAD

The most recent short interest data has been released for the 09/29/2017 settlement date, which shows a 10,064,113 share decrease in total short interest for Acadia Pharmaceuticals Inc , to 6,510,387, a decrease of 60.72% since 09/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

TheStreet Quant Rating: D- (Sell)